ASGP-R介导放射性标记肿瘤坏死因子防治肝癌的可行性

The Feasibility of Radiolabeled TNF Mediated by ASGP-R Against Hepatic Carcinoma

利用肝细胞膜表面的无唾液酸糖蛋白受体(ASGP-R)所能识别的配基作为载体,与放射性标记的肿瘤坏死因子(TNF)相结合,获得肝靶向放射性标记肿瘤坏死因子,使得肿瘤坏死因子选择性地导向肝脏,局部作用于肿瘤细胞,降低肿瘤坏死因子的毒副作用,从而提高靶与非靶比,促进肝癌细胞凋亡;防止肝癌术后复发,提高缓解率。因此,ASGP-R可能成为较理想的肝癌靶向放射性和生物治疗双效药物。

The asialoglycoprotein receptor(ASGPR) localizes on the parenchymal liver cells, by coupling with the special ligands radiolabeled tumor necrosis factor, it can selectively direct to the liver cells. It is promising hepatic targeting radiolabeled tumor necrosis factor which can act locally on hepatic carcinoma, improve the ratio of liver to nonliver, and reduce the side effect in order to developing the anticarcinoma action of TNF and increasing the apoptosis of hepatic carcinoma. The study aim is to reduce or prevent the recurrence of postoperated liver cancer and improve the remission to develop the biefficacy drugs both radioactivity and biological therapy on hepatic targeting